Skip to main content
SpringerLink
Log in

Costs of Bipolar Disorder

  • Review Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Bipolar disorder is a chronic affective disorder that causes significant economic burden to patients, families and society. It has a lifetime prevalence of approximately 1.3%. Bipolar disorder is characterised by recurrent mania or hypomania and depressive episodes that cause impairments in functioning and health-related quality of life. Patients require acute and maintenance therapy delivered via inpatient and outpatient treatment. Patients with bipolar disorder often have contact with the social welfare and legal systems; bipolar disorder impairs occupational functioning and may lead to premature mortality through suicide.

This review examines the symptomatology of bipolar disorder and identifies those features that make it difficult and costly to treat. Methods for assessing direct and indirect costs are reviewed. We report on comprehensive cost studies as well as administrative claims data and program evaluations. The majority of data is drawn from studies conducted in the US; however, we discuss European studies when appropriate.

Only two comprehensive cost-of-illness studies on bipolar disorder, one prevalence-based and one incidence-based, have been reported. There are, however, several comprehensive cost-of-illness studies measuring economic burden of affective disorders including bipolar disorder. Estimates of total costs of affective disorders in the US range from $US30.4–43.7 billion (1990 values). In the prevalence-based cost-of-illness study on bipolar disorder, total annual costs were estimated at $US45.2 billion (1991 values). In the incidence-based study, lifetime costs were estimated at $US24 billion.

Although there have been recent advances in pharmacotherapy and outpatient therapy, hospitalisation still accounts for a substantial portion of the direct costs. A variety of outpatient services are increasingly important for the care of patients with bipolar disorder and costs in this area continue to grow.

Indirect costs due to morbidity and premature mortality comprise a large portion of the cost of illness. Lost workdays or inability to work due to the disease cause high morbidity costs. Intangible costs such as family burden and impaired health-related quality of life are common, although it has proved difficult to attach monetary values to these costs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1

Similar content being viewed by others

References

  1. Murray CJ, Lopez AD, editors. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge (MA): Harvard University Press, 1996

    Google Scholar 

  2. Goldman HH, Rye P, Sirovatha P (editors). Mental health: a report of the Surgeon General. Washington, DC: Department of Health and Human Services, 1999

    Google Scholar 

  3. Goodwin FK, Jamison K. Manic depressive illness. New York: Oxford University Press, 1990

    Google Scholar 

  4. American Psychiatric Association. Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 1994; 151 (12 Suppl.): S1–S36

    Google Scholar 

  5. Weissman MM, Bruce ML, Leaf PJ, et al. Affective disorders. In: Robins LN, Regier DA, editors. Psychiatric disorders in America: the epidemiologic catchment area study. New York: The Free Press, a division of Macmillan Inc, 1991

    Google Scholar 

  6. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994; 51: 8–19

    Article  PubMed  CAS  Google Scholar 

  7. Kessler RC, Rubinow DR, Holmes C, et al. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997; 27: 1079–89

    Article  PubMed  CAS  Google Scholar 

  8. Kovess V, Gysens S, Chanoit PF, et al. Une enquête de santé mentale: l’enquête de santé des fanciliens. Ann Med Psychol 1993; 151: 624–8

    Google Scholar 

  9. Kovess V, Gysens S, Poinsard R, et al. La psychiatrie face aux problèmes sociaux: la prise en charge des RMIstes à Paris. ĽInformation Psychiatrique 1995; 3: 273–85

    Google Scholar 

  10. Wittchen HU, Essau CA, von Zerssen D, et al. Lifetime and six-month prevalence of mental disorders in the Munich Follow-up Study. Eur Arch Psychiatry Clin Neurosci 1992; 241: 247–58

    Article  PubMed  CAS  Google Scholar 

  11. Szadoczky E, Papp Z, Vitrai J, et al. The prevalence of major depressive and bipolar disorders in Hungary: results from a national epidemiologic survey. J Affect Disord 1998; 50 (2–3): 153–62

    Article  PubMed  CAS  Google Scholar 

  12. Faravelli C, Guerrini Degl’Innocenti B, Aiazzi L, et al. Epidemiology of mood disorders: a community survey in Florence. J Affect Disord 1990; 20: 135–41

    Article  PubMed  CAS  Google Scholar 

  13. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50 (2–3): 153–62

    Google Scholar 

  14. Weissman MM, Leaf PJ, Tischler GL, et al. Affective disorders in five United States communities. Psychol Med 1988; 18 (1): 141–53

    Article  PubMed  CAS  Google Scholar 

  15. Criado-Alvarez JJ, Domper Tornil JA, de la Rosa Rodriuez G. Estimate of type I bipolar disorder prevalence (1996–1998). Rev Esp Salud Publica 2000; 74 (2): 131–8

    Article  PubMed  CAS  Google Scholar 

  16. Canals J, Domenech E, Carbajo G, et al. Prevalence of DSM-III-R and ICD-10 psychiatric disorders in a Spanish population of 18-year-olds. Acta Psychiatr Scand 1997; 96 (4): 287–94

    Article  PubMed  CAS  Google Scholar 

  17. Halldin J. Prevalence of mental disorder in an urban population in central Sweden. Acta Psychiatr Scand 1984; 69 (6): 503–18

    Article  PubMed  CAS  Google Scholar 

  18. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol 1998; 33 (12): 587–95

    Article  PubMed  CAS  Google Scholar 

  19. van Os J, Hanssen M, Bijl RV, et al. Prevalence of psychotic disorder and community level of psychotic symptoms: an urban-rural comparison. Arch Gen Psychiatry 2001; 58 (7): 663–8

    Article  PubMed  Google Scholar 

  20. Suppes T, Dennehy EB, Wells Gibbons E. The longitudinal course of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 9: 23–30

    PubMed  Google Scholar 

  21. Roy-Byrne P, Post RM, Uhde TW, et al. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatr Scand Suppl 1985; 317: 1–34

    Article  PubMed  CAS  Google Scholar 

  22. Tondo L, Baldessarini RJ. Rapid cycling in women and men with bipolar manic-depressive disorders. Am J Psychiatry 1998; 155 (10): 1434–6

    PubMed  CAS  Google Scholar 

  23. Kessler RC. Comorbidity of unipolar and bipolar depression with other psychiatric disorders in a general population survey. In: Tohen M, editor. Comorbidity in affective disorders. New York: Marcel Dekker Inc. 1999: 1–25

    Google Scholar 

  24. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th, 9th ed. Washington, DC: American Psychiatric Association, 1999

    Google Scholar 

  25. Strakowski SM, Mauricio T, Stoll AL, et al. Comorbidity in mania at first hospitalization. Am J Psychiatry 1992; 149 (4): 554–6

    PubMed  CAS  Google Scholar 

  26. Keck PE, McElroy SL, Strakowski SM, et al. 12-month outcome of patients with bipolar disorder following hospitalization for a manic or mixed episode. Am J Psychiatry 1998; 155: 646–52

    PubMed  Google Scholar 

  27. Merikangas KR, Mehta RL, Molnar BE, et al. Comorbidity of substance use disorders with mood and anxiety disorders: results of the International Consortium in Psychiatric Epidemiology. Addict Behav 1998; 23 (6): 893–907

    Article  PubMed  CAS  Google Scholar 

  28. Dion GL, Tohen M, Anthony WA, et al. Symptoms and functioning of patients with bipolar disorder six months after hospitalization. Hosp Community Psychiatry 1988; 139: 652–7

    Google Scholar 

  29. Coryell W, Scheftner W, Keller M, et al. The enduring psychosocial consequences of mania and depression. Am J Psychiatry 1993; 150 (5): 720–7

    PubMed  CAS  Google Scholar 

  30. Leidy NK, Palmer C, Murray M, et al. Health-related quality of life assessment in euthymic and depressed patients with bipolar disorder: psychometric performance of four self-report measures. J Affect Disord 1998; 48: 207–14

    Article  PubMed  CAS  Google Scholar 

  31. Cooke RG, Robb JC, Young LT, et al. Well-being and functioning in patients with bipolar disorder assessed using the MOS 20-ITEM short form (SF-20). J Affect Disord 1996; 39: 93–7

    Article  PubMed  CAS  Google Scholar 

  32. Revicki DA, Tohen M, Gyulai L, et al. Telephone versus Inperson clinical and health status assessment interviews in patients with bipolar disorder. Harv Rev Psychiatry 1997; 5: 75–81

    Article  PubMed  CAS  Google Scholar 

  33. Wells KB, Sherbourne CD. Functioning and utility for current health of patients with depression or chronic medical conditions in managed, primary care practices. Arch Gen Psychiatry 1999; 56 (10): 897–904

    Article  PubMed  CAS  Google Scholar 

  34. Arnold LM, Witzeman KA, Swank ML, et al. Health-related quality of life using the SF-36 in patients with bipolar disorder compared with patients with chronic back pain and the general population. J Affect Disord 2000; 57: 235–9

    Article  PubMed  CAS  Google Scholar 

  35. Revicki DA, Hirschfeld R, Keck P, et al. Cost-effectiveness of divalproex sodium vs lithium for bipolar disorder. Washington, DC: Mental health Services Research, 2000 Jul

    Google Scholar 

  36. Meeks S. Bipolar disorder in the latter half of life: symptom presentation, global functioning and age of onset. J Affect Disord 1999; 52: 161–7

    Article  PubMed  CAS  Google Scholar 

  37. Hammen C, Gitlin M, Altshuler L. Predictors of work adjustment in bipolar I patients: a naturalistic longitudinal follow-up. J Consult Clin Psychol 2000; 68: 220–5

    Article  PubMed  CAS  Google Scholar 

  38. Bauer MS, Callahan AM, Jampala C, et al. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 1999; 60: 9–21

    Article  PubMed  CAS  Google Scholar 

  39. Dennehy EB, Suppes T. Medication algorithms for bipolar disorder. J Pract Psychiatry Behav Health 1999; 5: 142–52

    Google Scholar 

  40. Kahn D, Frances A, Docherty J, et al. Expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiatry 1996; 57 Suppl. 12A: 1–89

    Google Scholar 

  41. Altshuler LL, Gitlin M, Frye M, et al. Risk of depressive relapse in bipolar patients when antidepressants are discontinued. Biplor Disord 1999; 1 Suppl.: 22–3

    Google Scholar 

  42. Goldberg IF. Treatment guidelines: current and future management of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 13: 12–7

    PubMed  Google Scholar 

  43. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999; 156: 702–9

    PubMed  CAS  Google Scholar 

  44. Tohen M, Baker RW, Alsulter L, et al. Olanzapine versus divalproex for the treatment of acute mania. The annual meeting of the European College of Neuropsychopharmacology; 2000 Sep 9–13; Munich, Germany

  45. American Psychiatric Association. The practice of electroconvulsive therapy: recommedations for treatment, training and privileging: a task force report of the American Psychiatric Association, 2nd edition. Washington DC: American Psychiatric Press, 2001

    Google Scholar 

  46. Thase ME, Buysse DJ, Frank E, et al. Which depressed patients will respond to interpersonal psychotherapy: the role of abnormal EEG sleep profiles. Am J Psychiatry 1997; 154: 502–9

    PubMed  CAS  Google Scholar 

  47. British Medical Association. British national formulary. 40th ed. London: BMJ Books, 2000

    Google Scholar 

  48. The Bethlem & Maudsley NHS Trust 1999. Prescribing guidelines. 5th ed. London: Dunitz M, 1999

    Google Scholar 

  49. DGPPN. Behandlungsleitlinien affektive erkrankungen. Darmstadt, Steinkopf: Praxisleitlinien in Psychiatrie and Psychotherapie, 2000

    Google Scholar 

  50. Vieta E. Ensayo abierte sobre la eficacia y la seguridad del topiramato en el trastorno bipolar resistente. Programa de Trastornos bipolares. (Hospital Clínic de Barcelona) (Institute de Psiquiatría) Psicologiq Clínica y Salud Mental, 1998 Nov

    Google Scholar 

  51. Hess D, Ciompi L, Dauwalder HP. Nutzen- and Kosten-Evaluation eines sozialpsychiatrischen Dienstes. Nervenarzt 1986; 57 (4): 204–13

    PubMed  CAS  Google Scholar 

  52. Reetz-Kokott U, Muller-Oerlinghausen B. Has drug treatment of manic disorders changed in clinical routine practice?: retrospective analysis of treatment modalities and results in a university psychiatric clinic. Nervenartz 1996; 67: 229–34

    CAS  Google Scholar 

  53. Licht RW, Gouliaev G, Vestergaard P, et al. Treatment of manic episodes in Scandinavia: the use of neuroleptic drugs in a clinical routine setting. J Affect Disord 1994; 32: 179–85

    Article  PubMed  CAS  Google Scholar 

  54. Hill RG, Hardy P, Shepherd G. Perspectives on manic depression: a survey of the Manic Depression Fellowship. London, UK: The Sainsbury Centre for Mental Health, 1996

    Google Scholar 

  55. Goodwin GM. Prophylaxis of bipolar disorder: how and who should we treat in the long term? Eur-Neuropsychopharmacol 1999; 9 Suppl. 4: S125–9

    Article  PubMed  CAS  Google Scholar 

  56. Tohen M, Waternaux CM, Tsuang MT. Outcomes in mania: a 4-year follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry 1990; 47: 1101–6

    Article  Google Scholar 

  57. Goldberg IF, Harrow M, Grossman LS. Course and outcome in bipolar affective disorder: a longitudinal follow-up study. Am J Psychiatry 1995; 152 (3): 379–84

    PubMed  CAS  Google Scholar 

  58. Bowden CL. Efficacy of lithium in mania and maintenance therapy of bipolar disorder. J Clin Psychiatry 2000; 61 Suppl. 9: 35–40

    PubMed  CAS  Google Scholar 

  59. Harrow M, Goldberg IF, Grossman LS, et al. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47: 665–71

    Article  PubMed  CAS  Google Scholar 

  60. O’Connell RA, Mayo JA, Flatow L, et al. Outcome of bipolar disorder on long-term treatment with lithium. Br J Psychiatry 1991; 159: 123–9

    Article  PubMed  Google Scholar 

  61. Tsuang MT, Dempsey GM. Long-term outcome of major psychoses: II. schizoaffective disorder compared with schizophrenia, affective disorders, and a surgical control group. Arch Gen Psychiatry 1997; 36 (12): 1302–4

    Article  Google Scholar 

  62. Coryell W, Endicott J, Keller M. Rapidly cycling affective disorder: demographics, diagnosis, family history, and course. Arch Gen Psychiatry 1992; 49: 126–31

    Article  PubMed  CAS  Google Scholar 

  63. Guze S, Robins E. Suicide and primary affective disorders. Br J Psychiatry 1970; 117: 437–8

    Article  PubMed  CAS  Google Scholar 

  64. Jamison KR. Suicide and bipolar disorders. Ann N Y Acad Sci 1986; 487: 301–15

    Article  PubMed  CAS  Google Scholar 

  65. Kessler RC. The national comorbidity survey of the United States. Int Rev Psychiatry 1994; 6: 8–19

    Article  Google Scholar 

  66. Walsh E, Harvey K, White I, et al. Prevalence and predictors of parasuicide in chronic psychosis. UK700 group. Acta Psychiatr Scand 1999; 100 (5): 375–82

    Article  PubMed  CAS  Google Scholar 

  67. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994; 31 (2): 91–6

    Article  PubMed  CAS  Google Scholar 

  68. Ahrens B, Berghofer A, Wolf T, et al. Suicide attempts, age and duration of illness in recurrent affective disorders. J Affect Disord 1995; 36: 43–9

    Article  PubMed  CAS  Google Scholar 

  69. Tondo L, Baldessarini RJ, Hennen J, et al. Lithium treatment and risk of suicidal behavior in bipolar disorder patients. J Clin Psychiatry 1998; 59 (8): 405–14

    Article  PubMed  CAS  Google Scholar 

  70. Thies-Flecthner K, Muller-Oerlinghausen B, Seibert W, et al. Effect of prophylactic treatment on suicide risk in patients with major affective disorders: data from a randomized prospective trial. Pharmacopsychiatry 1996; 29: 102–7

    Google Scholar 

  71. Cooper BS, Rice DP. The economic cost of illness revisited. Soc Secur Bull 1976; 39: 21–36

    PubMed  CAS  Google Scholar 

  72. Hartunian NS, Smart CN, Thompson MS. The incidence and economic costs of major health impairments. Lexington (MA): Lexington Books, 1981

    Google Scholar 

  73. Rice DP, Kelman S, Miller LS, et al. The economic costs of alcohol and drug abuse and mental health illness: 1985. Report submitted to the Office of Financing and Coverage Policy of the Alcohol, Drug Abuse and Mental Health Administration, US Department of Health and Human Services. San Francisco (CA): Institute for Health & Aging, University of California, 1990

    Google Scholar 

  74. Hodgson TA, Meiners M. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982; 60 (3): 429–62

    Article  PubMed  CAS  Google Scholar 

  75. Hodgson TA. The state of the art of cost-of-illness estimates. Adv Health Econ Health Serv Res 1983; 4: 129–64

    PubMed  CAS  Google Scholar 

  76. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54: 405–18

    PubMed  CAS  Google Scholar 

  77. Clark RE, Teague GB, Ricketts SK, et al. Cost-effectiveness of assertive community treatment versus standard case management for persons with co-occurring severe mental illness and substance use disorder. Health Serv Res 1998; 33: 1285–308

    PubMed  CAS  Google Scholar 

  78. Quinliven R, Hough R, Crowell A, et al. Service utilization and costs of care for severely mentally ill clients in an intensive case management program. Psychiatr Serv 1995; 46: 365–71

    Google Scholar 

  79. Rice DP, Miller LS. The economic burden of affective disorders. Adv Health Econ Health Serv Res 1993; 14: 37–53

    PubMed  CAS  Google Scholar 

  80. Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness: 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 213–9

    PubMed  CAS  Google Scholar 

  81. Begley CE, Annegers IF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001; 19 (5 Pt 1): 483–95

    Article  PubMed  CAS  Google Scholar 

  82. Johnstone B, Loosbrock DL, Morris LS, et al. Estimated costs of treatment for bipolar disorder in a large employer database. The 128th Annual Meeting of APHA; 2000 Nov 14; Boston (MA)

  83. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999; 50 (10): 1303–8

    PubMed  CAS  Google Scholar 

  84. Jonsson B, Bebbington PE. What price depression?: the cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164: 665–73

    Article  PubMed  CAS  Google Scholar 

  85. Amaddeo F, Beecham J, Bonizzato P, et al. The costs of community-based psychiatric care for first-ever patients: a case register study. Psychol Med 1998; 28 (1): 173–83

    Article  PubMed  CAS  Google Scholar 

  86. Amaddeo F, Bonizzato P, Tansella M. Psychiatric case registers for monitoring service utilization and evaluating its costs. In: Il Pensiero Scientifico, Tansella M, editor. Making rational mental health services. Roma: 1997: 177–98

    Google Scholar 

  87. Dardennes R, Lafuma A, Watkins S. Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine. Encephale 1999; 25 (5): 391–400

    PubMed  CAS  Google Scholar 

  88. A history of mental health and community care. London, UK: MIND, 2000

  89. Lish JD, Dime-Meenan S, Whybrow PC, et al. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31: 281–94

    Article  PubMed  CAS  Google Scholar 

  90. Narrow WE, Regier DA, Rae DS, et al. Use of services by persons with mental and addictive disorders: findings from the National Institute of Mental Health Epidemiologic Catchment Area Program. Arch Gen Psychiatry 1993; 50: 95–107

    Article  PubMed  CAS  Google Scholar 

  91. Hospital episode statistics. 1996/97. London, Department of Health, 2000

  92. AOK-Bundesverband, editor. AOK-Bundesverband. Krankheitsartenstatistik 1997. Bonn: Krankheitsartenstatistik, 1999

  93. Scottish Morbidity Record 1. 1997/98. NHS Scotland: Information and Statistics Division, 2000

  94. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990; 264: 2511–8

    Article  PubMed  CAS  Google Scholar 

  95. Royal College of General Practitioners and Office of Population Censuses and Surveys. Morbidity statistics from general practice: fourth national study 1991–1992. London: HMSO, 1995

    Google Scholar 

  96. Woods SW. The economic burden of bipolar disease. J Clin Psychiatry 2000; 61 Suppl. 13: 38–41

    PubMed  Google Scholar 

  97. Galvin PM, Knezek LD, Rush AJ, et al. Clinical and economic impact of newer versus older antipsychotic medication in a community mental health center. Clin Ther 1999; 22 (6): 1105–16

    Article  Google Scholar 

  98. Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998; 173 Suppl. 34: 4–9

    Google Scholar 

  99. Franks DD. Economics contribution of families for persons with severe and persistent mental illness. Adm Policy Ment Health 1990; 18: 9–12

    Article  Google Scholar 

  100. OFISALUD and Bernard Krieff Sociological Studies Office. El coste social de los trastornos de salud mental en España. SmithKline Beecham Pharmaceuticals, 1998

    Google Scholar 

  101. Keck PE, Nabulsi AA, Taylor JL, et al. A pharmacoeconomic model of Divalproex vs Lithium in the acute and prophylactic treatment of bipolar disorder. J Clin Psychiatry 1996; 57 (5): 213–22

    PubMed  CAS  Google Scholar 

  102. Baker CB, Woods SW, Sernyak MI. Cost-effectiveness of divalproex versus lithium [letter]. J Clin Psychiatry 1997, 58 (8): 363

    Article  PubMed  CAS  Google Scholar 

  103. Revicki DA, Luce BR. Methods of pharmacoeconomic evaluation of new medical treatments in psychiatry. Pharmacol Bull 1995; 31: 57–65

    CAS  Google Scholar 

  104. Revicki DA, Paramore CL, Sommerville KW, et al. Divalproex sodium versus olanzapine in the treatment of bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003; 64: 288–94

    Article  PubMed  CAS  Google Scholar 

  105. Namjoshi M, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania: results from a randomized controlled trial. J Affect Disord 2001; 69: 109–18

    Article  Google Scholar 

  106. Sanger T, Namjoshi M, Gibson P, et al. Long-term olanzapine therapy in the stabilization and maintenance treatment of bipolar I disorder: an open label continuation phase study. J Clin Psychiatry 2001; 62: 273–81

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to acknowledge Barbara Suggs for her assistance in the manuscript preparation. Funding for this project was provided, in part, by Eli Lilly Inc.

Author information

Authors and Affiliations

  1. MEDTAP International Inc, Bethesda, Maryland, USA

    Leah S. Kleinman, Emuella Flood & Dennis A. Revicki

  2. Fourth Hurdle Consulting Ltd, London, UK

    Ana Lowin

  3. Eli Lilly and Company Ltd, Surrey, UK

    Gian Gandhi & Eric Edgell

Authors
  1. Leah S. Kleinman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ana Lowin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Emuella Flood
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gian Gandhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Edgell
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dennis A. Revicki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kleinman, L.S., Lowin, A., Flood, E. et al. Costs of Bipolar Disorder. Pharmacoeconomics 21, 601–622 (2003). https://doi.org/10.2165/00019053-200321090-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200321090-00001

Keywords

Search

Navigation